Primary resistance to integrase strand-transfer inhibitors in Europe
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F75010330%3A_____%2F15%3A00011002" target="_blank" >RIV/75010330:_____/15:00011002 - isvavai.cz</a>
Result on the web
<a href="http://jac.oxfordjournals.org/content/70/10/2885" target="_blank" >http://jac.oxfordjournals.org/content/70/10/2885</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/jac/dkv202" target="_blank" >10.1093/jac/dkv202</a>
Alternative languages
Result language
angličtina
Original language name
Primary resistance to integrase strand-transfer inhibitors in Europe
Original language description
Objectives: The objective of this study was to define the natural genotypic variation of the HIV-1 integrase gene across Europe for epidemiological surveillance of integrase strand-transfer inhibitor (InSTI) resistance. Methods: This was a multicentre, cross-sectional study within the European SPREAD HIV resistance surveillance programme. A representative set of 300 samples was selected from 1950 naive HIV-positive subjects newly diagnosed in 2006-07. The prevalence of InSTI resistance was evaluated using quality-controlled baseline population sequencing of integrase. Signature raltegravir, elvitegravir and dolutegravir resistance mutations were defined according to the IAS-USA 2014 list. In addition, all integrase substitutions relative to HXB2 were identified, including those with a Stanford HIVdb score greater or equal 10 to at least one InSTI. To rule out circulation of minority InSTI-resistant HIV, 65 samples were selected for 454 integrase sequencing. Results: For the population sequencing analysis, 278 samples were retrieved and successfully analysed. No signature resistance mutations to any of the InSTIs were detected. Eleven (4%) subjects had mutations at resistance-associated positions with an HIVdb score greater or equal 10. Of the 56 samples successfully analysed with 454 sequencing, no InSTI signature mutations were detected, whereas integrase substitutions with an HIVdb score greater or equal 10 were found in 8 (14.3%) individuals. Conclusions: No signature InSTI-resistant variants were circulating in Europe before the introduction of InSTIs. However, polymorphisms contributing to InSTI resistance were not rare. As InSTI use becomes more widespread, continuous surveillance of primary InSTI resistance is warranted. These data will be key to modelling the kinetics of InSTI resistance transmission in Europe in the coming years.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FN - Epidemiology, infection diseases and clinical immunology
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Antimicrobial Chemotherapy
ISSN
0305-7453
e-ISSN
—
Volume of the periodical
70
Issue of the periodical within the volume
10
Country of publishing house
GB - UNITED KINGDOM
Number of pages
4
Pages from-to
2885-2888
UT code for WoS article
000363249800028
EID of the result in the Scopus database
—